Literature DB >> 34927079

Are the estrogen receptor and SIRT3 axes of the mitochondrial UPR key regulators of breast cancer sub-type determination according to age?

Edmund Charles Jenkins1, Mrittika Chattopadhyay1, Doris Germain1.   

Abstract

Aging is a major risk factor of developing breast cancer. Despite the fact that post-menopausal women have lower levels of estrogen, older women have a higher rate of estrogen receptor alpha (ERα) positive breast cancer. Conversely, young women who have elevated levels of estrogen tend to develop ERα negative disease that is associated with higher rate of metastasis. This perspective proposes a unifying model centered around the importance of mitochondrial biology in cancer and aging to explain these observations. Mitochondria are essential for the survival of cancer cells and therefore pathways that maintain the functionality of the mitochondrial network in cancer cells fulfill a critical role in the survival of cancer cells. The ERα and the mitochondrial sirtuin-3 (SIRT3) have been reported to be key players of the mitochondrial unfolded protein response (UPRmt) 1-5. The UPRmt is a complex retrograde signaling cascade that regulates the communication between the mitochondria and the nucleus to restore mitochondrial fitness in response to oxidative stress 5-7. SIRT3 is a major regulator of aging 8. Its level decreases with age and single nucleotide polymorphisms (SNPs) that preserve its expression at higher levels are observed in centenarians 9,10. We propose a model whereby the ERα axis of the UPRmt acts to compensate for the loss of SIRT3 observed with age, and becomes the dominant axis of the UPRmt to maintain the integrity of the mitochondria during transformation, thus explaining the selective advantage of ERα positive luminal cells in breast cancer arising from older women.

Entities:  

Keywords:  Breast cancer; SIRT3; aged breast; aging; estrogen receptor alpha; mitochondria; mitochondrial unfolded protein response

Year:  2021        PMID: 34927079      PMCID: PMC8680335          DOI: 10.1002/aac2.12035

Source DB:  PubMed          Journal:  Aging Cancer        ISSN: 2643-8909


  61 in total

Review 1.  Targeting the 26S Proteasome To Protect Against Proteotoxic Diseases.

Authors:  Natura Myeku; Karen E Duff
Journal:  Trends Mol Med       Date:  2017-12-09       Impact factor: 11.951

2.  Mitochondrial Sirtuin Network Reveals Dynamic SIRT3-Dependent Deacetylation in Response to Membrane Depolarization.

Authors:  Wen Yang; Koji Nagasawa; Christian Münch; Yingjie Xu; Kyle Satterstrom; Seungmin Jeong; Sebastian D Hayes; Mark P Jedrychowski; F Sejal Vyas; Elma Zaganjor; Virginia Guarani; Alison E Ringel; Steven P Gygi; J Wade Harper; Marcia C Haigis
Journal:  Cell       Date:  2016-10-27       Impact factor: 41.582

3.  Heterogeneity of oestrogen receptor expression in normal and malignant breast tissue.

Authors:  K J Walker; R A McClelland; W Candlish; R W Blamey; R I Nicholson
Journal:  Eur J Cancer       Date:  1992       Impact factor: 9.162

Review 4.  Neuronal aggregates: formation, clearance, and spreading.

Authors:  Junghyun Lim; Zhenyu Yue
Journal:  Dev Cell       Date:  2015-02-23       Impact factor: 12.270

5.  SirT3 regulates the mitochondrial unfolded protein response.

Authors:  Luena Papa; Doris Germain
Journal:  Mol Cell Biol       Date:  2013-12-09       Impact factor: 4.272

6.  Mitochondrial Sirt3 supports cell proliferation by regulating glutamine-dependent oxidation in renal cell carcinoma.

Authors:  Jieun Choi; Eunjin Koh; Yu Shin Lee; Hyun-Woo Lee; Hyeok Gu Kang; Young Eun Yoon; Woong Kyu Han; Kyung Hwa Choi; Kyung-Sup Kim
Journal:  Biochem Biophys Res Commun       Date:  2016-04-23       Impact factor: 3.575

Review 7.  Sirt3, mitochondrial ROS, ageing, and carcinogenesis.

Authors:  Seong-Hoon Park; Ozkan Ozden; Haiyan Jiang; Yong I Cha; J Daniel Pennington; Nukhet Aykin-Burns; Douglas R Spitz; David Gius; Hyun-Seok Kim
Journal:  Int J Mol Sci       Date:  2011-09-23       Impact factor: 5.923

8.  Sirtuin-3 (SIRT3), a novel potential therapeutic target for oral cancer.

Authors:  Turki Y Alhazzazi; Pachiyappan Kamarajan; Nam Joo; Jing-Yi Huang; Eric Verdin; Nisha J D'Silva; Yvonne L Kapila
Journal:  Cancer       Date:  2010-11-29       Impact factor: 6.860

9.  Mitohormesis Primes Tumor Invasion and Metastasis.

Authors:  Timothy C Kenny; Amanda J Craig; Augusto Villanueva; Doris Germain
Journal:  Cell Rep       Date:  2019-05-21       Impact factor: 9.423

Review 10.  The interrelationship of proteasome impairment and oligomeric intermediates in neurodegeneration.

Authors:  Jennifer M Deger; Julia E Gerson; Rakez Kayed
Journal:  Aging Cell       Date:  2015-06-05       Impact factor: 9.304

View more
  1 in total

Review 1.  Estrogen signaling as a bridge between the nucleus and mitochondria in cardiovascular diseases.

Authors:  Emanuel Guajardo-Correa; Juan Francisco Silva-Agüero; Ximena Calle; Mario Chiong; Mauricio Henríquez; Gerardo García-Rivas; Mauricio Latorre; Valentina Parra
Journal:  Front Cell Dev Biol       Date:  2022-09-14
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.